Filtered By:
Infectious Disease: Hepatitis C
This page shows you your search results in order of date. This is page number 17.
Order by Relevance | Date
Total 11826 results found since Jan 2013.
Efficacy and safety of sofosbuvir-velpatasvir and sofosbuvir-velpatasvir-voxilaprevir for hepatitis C in Korea: a Phase 3b study
CONCLUSION: Treatment with sofosbuvir-velpatasvir or sofosbuvir-velpatasvir-voxilaprevir was safe and resulted in high SVR12 rates in Korean HCV patients.PMID:37424500 | PMC:PMC10338242 | DOI:10.3904/kjim.2022.252
Source: The Korean Journal of Internal Medicine - July 10, 2023 Category: Internal Medicine Authors: Jeong Heo Yoon Jun Kim Sung Wook Lee Youn-Jae Lee Ki Tae Yoon Kwan Soo Byun Yong Jin Jung Won Young Tak Sook-Hyang Jeong Kyung Min Kwon Vithika Suri Peiwen Wu Byoung Kuk Jang Byung Seok Lee Ju-Yeon Cho Jeong Won Jang Soo Hyun Yang Seung Woon Paik Hyung Jo Source Type: research
Sofosbuvir-velpatasvir and sofosbuvir-velpatasvir-voxilaprevir: novel treatment options for na ïve and previously treated hepatitis C infection
Korean J Intern Med. 2023 Jul;38(4):454-455. doi: 10.3904/kjim.2023.248. Epub 2023 Jun 30.NO ABSTRACTPMID:37424499 | PMC:PMC10338249 | DOI:10.3904/kjim.2023.248
Source: The Korean Journal of Internal Medicine - July 10, 2023 Category: Internal Medicine Authors: Hyun Phil Shin Source Type: research
Efficacy and safety of sofosbuvir-velpatasvir and sofosbuvir-velpatasvir-voxilaprevir for hepatitis C in Korea: a Phase 3b study
CONCLUSION: Treatment with sofosbuvir-velpatasvir or sofosbuvir-velpatasvir-voxilaprevir was safe and resulted in high SVR12 rates in Korean HCV patients.PMID:37424500 | PMC:PMC10338242 | DOI:10.3904/kjim.2022.252
Source: The Korean Journal of Internal Medicine - July 10, 2023 Category: Internal Medicine Authors: Jeong Heo Yoon Jun Kim Sung Wook Lee Youn-Jae Lee Ki Tae Yoon Kwan Soo Byun Yong Jin Jung Won Young Tak Sook-Hyang Jeong Kyung Min Kwon Vithika Suri Peiwen Wu Byoung Kuk Jang Byung Seok Lee Ju-Yeon Cho Jeong Won Jang Soo Hyun Yang Seung Woon Paik Hyung Jo Source Type: research
Sofosbuvir-velpatasvir and sofosbuvir-velpatasvir-voxilaprevir: novel treatment options for na ïve and previously treated hepatitis C infection
Korean J Intern Med. 2023 Jul;38(4):454-455. doi: 10.3904/kjim.2023.248. Epub 2023 Jun 30.NO ABSTRACTPMID:37424499 | PMC:PMC10338249 | DOI:10.3904/kjim.2023.248
Source: The Korean Journal of Internal Medicine - July 10, 2023 Category: Internal Medicine Authors: Hyun Phil Shin Source Type: research
Efficacy and safety of sofosbuvir-velpatasvir and sofosbuvir-velpatasvir-voxilaprevir for hepatitis C in Korea: a Phase 3b study
CONCLUSION: Treatment with sofosbuvir-velpatasvir or sofosbuvir-velpatasvir-voxilaprevir was safe and resulted in high SVR12 rates in Korean HCV patients.PMID:37424500 | PMC:PMC10338242 | DOI:10.3904/kjim.2022.252
Source: The Korean Journal of Internal Medicine - July 10, 2023 Category: Internal Medicine Authors: Jeong Heo Yoon Jun Kim Sung Wook Lee Youn-Jae Lee Ki Tae Yoon Kwan Soo Byun Yong Jin Jung Won Young Tak Sook-Hyang Jeong Kyung Min Kwon Vithika Suri Peiwen Wu Byoung Kuk Jang Byung Seok Lee Ju-Yeon Cho Jeong Won Jang Soo Hyun Yang Seung Woon Paik Hyung Jo Source Type: research
Sofosbuvir-velpatasvir and sofosbuvir-velpatasvir-voxilaprevir: novel treatment options for na ïve and previously treated hepatitis C infection
Korean J Intern Med. 2023 Jul;38(4):454-455. doi: 10.3904/kjim.2023.248. Epub 2023 Jun 30.NO ABSTRACTPMID:37424499 | PMC:PMC10338249 | DOI:10.3904/kjim.2023.248
Source: The Korean Journal of Internal Medicine - July 10, 2023 Category: Internal Medicine Authors: Hyun Phil Shin Source Type: research
Efficacy and safety of sofosbuvir-velpatasvir and sofosbuvir-velpatasvir-voxilaprevir for hepatitis C in Korea: a Phase 3b study
CONCLUSION: Treatment with sofosbuvir-velpatasvir or sofosbuvir-velpatasvir-voxilaprevir was safe and resulted in high SVR12 rates in Korean HCV patients.PMID:37424500 | PMC:PMC10338242 | DOI:10.3904/kjim.2022.252
Source: The Korean Journal of Internal Medicine - July 10, 2023 Category: Internal Medicine Authors: Jeong Heo Yoon Jun Kim Sung Wook Lee Youn-Jae Lee Ki Tae Yoon Kwan Soo Byun Yong Jin Jung Won Young Tak Sook-Hyang Jeong Kyung Min Kwon Vithika Suri Peiwen Wu Byoung Kuk Jang Byung Seok Lee Ju-Yeon Cho Jeong Won Jang Soo Hyun Yang Seung Woon Paik Hyung Jo Source Type: research
Sofosbuvir-velpatasvir and sofosbuvir-velpatasvir-voxilaprevir: novel treatment options for na ïve and previously treated hepatitis C infection
Korean J Intern Med. 2023 Jul;38(4):454-455. doi: 10.3904/kjim.2023.248. Epub 2023 Jun 30.NO ABSTRACTPMID:37424499 | PMC:PMC10338249 | DOI:10.3904/kjim.2023.248
Source: The Korean Journal of Internal Medicine - July 10, 2023 Category: Internal Medicine Authors: Hyun Phil Shin Source Type: research
Efficacy and safety of sofosbuvir-velpatasvir and sofosbuvir-velpatasvir-voxilaprevir for hepatitis C in Korea: a Phase 3b study
CONCLUSION: Treatment with sofosbuvir-velpatasvir or sofosbuvir-velpatasvir-voxilaprevir was safe and resulted in high SVR12 rates in Korean HCV patients.PMID:37424500 | PMC:PMC10338242 | DOI:10.3904/kjim.2022.252
Source: The Korean Journal of Internal Medicine - July 10, 2023 Category: Internal Medicine Authors: Jeong Heo Yoon Jun Kim Sung Wook Lee Youn-Jae Lee Ki Tae Yoon Kwan Soo Byun Yong Jin Jung Won Young Tak Sook-Hyang Jeong Kyung Min Kwon Vithika Suri Peiwen Wu Byoung Kuk Jang Byung Seok Lee Ju-Yeon Cho Jeong Won Jang Soo Hyun Yang Seung Woon Paik Hyung Jo Source Type: research
Sofosbuvir-velpatasvir and sofosbuvir-velpatasvir-voxilaprevir: novel treatment options for na ïve and previously treated hepatitis C infection
Korean J Intern Med. 2023 Jul;38(4):454-455. doi: 10.3904/kjim.2023.248. Epub 2023 Jun 30.NO ABSTRACTPMID:37424499 | PMC:PMC10338249 | DOI:10.3904/kjim.2023.248
Source: The Korean Journal of Internal Medicine - July 10, 2023 Category: Internal Medicine Authors: Hyun Phil Shin Source Type: research
Inhibitors Targeting Hepatitis C Virus (HCV) Entry
Mini Rev Med Chem. 2023;23(11):1193-1221. doi: 10.2174/1389557522666220428115152.ABSTRACTInfections caused by the Hepatitis C virus (HCV) affect around 70 million people worldwide, leading to serious liver problems, such as fibrosis, steatosis, and cirrhosis, in addition to progressing to hepatocellular carcinoma and becoming globally the main cause of liver disease. Despite great therapeutic advances in obtaining pan-genotypic direct-acting antivirals (DAAs), around 5-10% of affected individuals are unable to eliminate the virus by their own immune system's activity. Still, there are no licensed vaccines so far. In this c...
Source: Mini Reviews in Medicinal Chemistry - July 10, 2023 Category: Chemistry Authors: Paulo Fernando da Silva Santos-J únior Jo ão Xavier de Araújo-Júnior Edeildo Ferreira da Silva-J únior Source Type: research
Efficacy and safety of sofosbuvir-velpatasvir and sofosbuvir-velpatasvir-voxilaprevir for hepatitis C in Korea: a Phase 3b study
CONCLUSION: Treatment with sofosbuvir-velpatasvir or sofosbuvir-velpatasvir-voxilaprevir was safe and resulted in high SVR12 rates in Korean HCV patients.PMID:37424500 | PMC:PMC10338242 | DOI:10.3904/kjim.2022.252
Source: The Korean Journal of Internal Medicine - July 10, 2023 Category: Internal Medicine Authors: Jeong Heo Yoon Jun Kim Sung Wook Lee Youn-Jae Lee Ki Tae Yoon Kwan Soo Byun Yong Jin Jung Won Young Tak Sook-Hyang Jeong Kyung Min Kwon Vithika Suri Peiwen Wu Byoung Kuk Jang Byung Seok Lee Ju-Yeon Cho Jeong Won Jang Soo Hyun Yang Seung Woon Paik Hyung Jo Source Type: research
Sofosbuvir-velpatasvir and sofosbuvir-velpatasvir-voxilaprevir: novel treatment options for na ïve and previously treated hepatitis C infection
Korean J Intern Med. 2023 Jul;38(4):454-455. doi: 10.3904/kjim.2023.248. Epub 2023 Jun 30.NO ABSTRACTPMID:37424499 | PMC:PMC10338249 | DOI:10.3904/kjim.2023.248
Source: The Korean Journal of Internal Medicine - July 10, 2023 Category: Internal Medicine Authors: Hyun Phil Shin Source Type: research
Clinical performance of the MAGLUMI Anti-HCV (CLIA) Test for detection of hepatitis C virus antibodies
CONCLUSIONS: The performance of the MAGLUMI Anti-HCV (CLIA) Test makes it suited for HCV infection diagnosis.PMID:37419419 | DOI:10.1016/j.jviromet.2023.114770
Source: Journal of Virological Methods - July 7, 2023 Category: Virology Authors: Tinghua Li Hongwei Zhang Zhonggang Fang Jun Yin Wei Rao Source Type: research
